Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan + Cetuximab in Recurrent/Metastatic HNSCC
NCT07063212Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in head and neck squamous cell carcinoma (HNSCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate up to 2 years. Started Jul 2025; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07063212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063212.